- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Ravulizumab – March 2025
Ravulizumab; Solution concentrate for I.V. infusion 300 mg in 3 mL, Solution concentrate for I.V. infusion 1,100 mg in 11 mL; Ultomiris®
Last updated
12 March 2025